货号：DT2025061994
CAS：508201-30-7
规格：mg(更多包装需求请咨询客服)
纯度：≥98%
生产商：试剂家

生物活性：Tamoxifen-d3 is the deuterium labeled Tamoxifen[1]. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells[2][3][4]. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively[6]. Tamoxifen activates autophagy and induces apoptosis[5]. Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse[7].
体外研究(In Vitro)：氢、碳和其他元素的稳定重同位素已被掺入药物分子中，主要用作药物开发过程中定量的示踪剂。氘代因其可能影响药物的药代动力学和代谢特征而受到关注[1]。
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Tamoxifen-d3 相关抗体:
ERK1/2 Antibody
E-Cadherin Antibody (YA470)
Fatty Acid Synthase Antibody (YA766)
DYKDDDDK Tag (FLAG) Antibody
GAPDH Antibody
GFP Antibody
p53 Antibody (YA250)
RUNX2 Antibody
Ferritin Heavy Chain Antibody
Hsp70 1B Antibody
COX2 Antibody
Ctip2 Antibody
Cyclin D1 Antibody (YA485)
Cytochrome C Antibody
Hsp70 Antibody (YA359)
Hsp90 alpha Antibody
c-Myc Antibody
Cyclin E1 Antibody
Hsc70 Antibody
AIF Antibody (YA636)
ALIX Antibody
CNPase Antibody
Cortactin Antibody
COX IV Antibody
COX2/Cyclooxygenase 2 Antibody
Cyclin A2 Antibody
Cyclin B1 Antibody (YA486)
DR5 Antibody
Drosha Antibody
E-Cadherin Antibody (YA778)
分子量：374.53
Formula：C26H26D3NO
CAS 号：508201-30-7
非标记 CAS：10540-29-1
中文名称：他莫西芬-d3
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (542 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
 [Content Brief]
[2]. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26;339(22):1609-18.
 [Content Brief]
[3]. Hawariah A, et al. In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its antiestrogenicity. Anticancer Res. 1998 Nov-Dec18(6A):4383-6.
 [Content Brief]
[4]. Jun Nagai, et al. Hyperactivity with Disrupted Attention by Activation of an Astrocyte Synaptogenic Cue. Cell. 2019 May 16177(5):1280-1292.e20.
 [Content Brief]
[5]. Zhao R, et al. Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity. PLoS One. 2010 Apr 15(4):e9934.
 [Content Brief]
[6]. Kedjouar B, et al. Molecular characterization of the microsomal tamoxifen binding site. J Biol Chem. 2004 Aug 6279(32):34048-61.
 [Content Brief]
[7]. Laura Cooper, et al. Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem. 2020 Sep 4.
 [Content Brief]
[8]. Feil S, et, al. Inducible Cre mice. Methods Mol Biol. 2009530:343-63.
 [Content Brief]